Along with other tests, tumor marker tests can help doctors diagnose cancer and recommend treatment options for individuals. The reasons for, timing and frequency of these tests vary from person to person. Rarely, they are used to help screen people at high risk for specific types of cancer before signs and symptoms appear. CD BioSciences offers researchers biomarker testing for common cancers with its highly accurate cellular bioassay platform, and our comprehensive line of tumor markers and harmonized instruments provide laboratories with clinically meaningful results.
Clinical Significance of Tumor Markers
Tumor markers (TM) are substances produced by tumor cells themselves or produced abnormally by the body in response to tumor cells during the development and proliferation of malignant tumors, reflecting the existence and growth of tumors, including proteins, hormones, enzymes (isoenzymes), polyamines and oncogene products, etc. They exist in the blood, body fluids, cells, or tissues of patients. They can be measured by biochemistry, immunology and molecular biology, and are valuable for the auxiliary diagnosis, differential diagnosis, effect observation, recurrence monitoring and prognosis assessment of tumors.
Cytoskeleton as Tumor Biomarker
In addition to cell shape and support, the cytoskeleton facilitates many physiological processes, such as intracellular signaling and transport, as well as cancer-related processes such as proliferation, migration, and invasion. In the last decade, comparative proteomics studies have identified cytoskeletal proteins as in vitro markers of tumor progression and metastasis.
Detailed monitoring of cytoskeletal proteins in tumors and adjacent tissues may help to better predict disease progression. According to the protein atlas, not all cytoskeleton-related genes are expressed everywhere, and we suggest that absolute quantification of cytoskeletal proteins may be used as a measure to understand the physiological roles and regulation, as well as potential phenotypic readout biological processes to predict tumor progression with great accuracy.
Expression of smooth-muscle actin in desmoplastic stroma [1].
Our Services
Tumor markers are highly sensitive and specific and can be used to identify benign and malignant tumors. CD BioSciences has an experienced scientific team to provide tumor marker related development and analysis services to our clients.
Cytoskeleton-targeted Tumor Marker Discovery
Quantitative analysis of cytoskeletal proteins in healthy tissues, tumors, adjacent tissues and stroma is an important source of molecular information that can be used not only to classify tumors, but more importantly to predict patient prognosis or even the best treatment options. We offer a variety of biomarker discovery programs designed to accelerate your cytoskeletal tumor marker discovery program.
Cytoskeleton-targeted Tumor Biomarker Assay
Tumor Markers are chemical-like substances that reflect the presence of tumors. We offer LC-MS/MS technology for the detection of cytoskeletal tumor markers on tissue, blood and cell samples provided by our clients. Our biomarker bioanalytical services cover a wide range of cancer areas.
- Squamous Cell Carcinoma
- Adenocarcinoma
- Large Cell Carcinoma
- Small Cell Carcinoma
- Migratory Cell Carcinoma
- Cystic Adenocarcinoma
- Smooth Muscle Sarcoma
- Malignant Lymphoma
- Leukemia
Features
Advanced Biotechnology
Customizable Designs
Competitive Pricing
Best After-sales Service
CD BioSciences provides our global customers with cost effective, high quality and efficient research solutions for cytoskeleton related diseases. We guarantee on-time delivery of our products and results, please contact us for more details.
Reference
- Sinn M, et al. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study[J]. British journal of cancer, 2014, 111(10): 1917-1923.
For research use only. Not intended for any clinical use.
